2 weeks Ago By ABMN Staff
Neurocrine Biosciences ( NASDAQ:NBIX – Get Free Report ) had its price objective dropped by Royal Bank of Canada from $143.00 to $136.00 in a research note issued to investors on Thursday, Benzinga reports.
The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 7.04% from the stock’s previous close.
A number of other research firms also recently weighed in on NBIX. Oppenheimer upped their target price on Neurocrine Biosciences from $216.00 to $219.
00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $131.00 to $159.
00 in a research note on Thursday. Citigroup raised their price objective on Neurocrine Biosciences from $150.00 to $158.
00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Evercore ISI assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $175.
00 target price on the stock. Finally, StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th.
Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $163.00.
Get Our Latest Research Report on Neurocrine Biosciences Neurocrine Biosciences Trading Down 1.1 % Neurocrine Biosciences ( NASDAQ:NBIX – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.
63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52).
The company had revenue of $590.20 million for the quarter, compared to analysts’ expectations of $545.98 million.
Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%.
The firm’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.
95 earnings per share. Research analysts forecast that Neurocrine Biosciences will post 4.22 earnings per share for the current fiscal year.
Insiders Place Their Bets In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.
69, for a total value of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.
79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . In related news, Director William H.
Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.
50. Following the transaction, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, insider Julie Cooke sold 12,632 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $153.
26, for a total value of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at $2,789,638.
52. The disclosure for this sale can be found here . In the last quarter, insiders sold 71,798 shares of company stock valued at $10,676,096.
Company insiders own 4.30% of the company’s stock. Institutional Trading of Neurocrine Biosciences Institutional investors and hedge funds have recently modified their holdings of the company.
Cetera Investment Advisers raised its holdings in Neurocrine Biosciences by 7.9% during the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock valued at $979,000 after acquiring an additional 519 shares during the period.
Susquehanna Fundamental Investments LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter worth approximately $509,000. Lion Point Capital LP lifted its holdings in Neurocrine Biosciences by 11.3% in the 2nd quarter.
Lion Point Capital LP now owns 8,350 shares of the company’s stock worth $1,150,000 after purchasing an additional 850 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Neurocrine Biosciences by 0.9% in the 2nd quarter.
The Manufacturers Life Insurance Company now owns 125,401 shares of the company’s stock worth $17,264,000 after purchasing an additional 1,074 shares during the period. Finally, MBB Public Markets I LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $982,000. 92.
59% of the stock is currently owned by institutional investors. Neurocrine Biosciences Company Profile ( Get Free Report ) Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
